Tempus ECG-AF vs Cardiomo
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your healthcare facility needs an FDA-cleared AI algorithm to analyze standard 12-lead ECGs from patients 65 or older to identify those at increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for integrating into existing cardiology workflows to support earlier identification and follow-up for at-risk geriatric patients without a prior AF diagnosis or specific cardiac devices.
View Tempus ECG-AF →Choose Cardiomo if…
Choose Cardiomo if you require a medical-grade wearable device and AI-powered platform for continuous, remote heart health monitoring, particularly for detecting cardiovascular diseases and providing real-time alerts to users and caregivers. This solution is best suited for ongoing patient oversight, offering features like continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature) and fall detection, with data accessible via a mobile app and cloud analytics.
View Cardiomo →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Cardiomo |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based with wearable device and mobile app |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CardiomoCardiomo offers a wearable patch and mobile app for continuous, real-time monitoring, making it highly user-friendly for patients in their daily lives. Tempus ECG-AF, while integrated into healthcare systems, is a software solution for clinicians, requiring a traditional 12-lead ECG in a healthcare facility, which is less convenient for continuous patient use.
Clinical Value
Tempus ECG-AFTempus ECG-AF is an FDA-cleared algorithm specifically designed to identify patients aged 65 or older at increased risk of developing AF within 12 months, with its clinical performance validated in multi-site studies. Cardiomo, while offering continuous monitoring and AI-powered disease detection, mentions applying for FDA approval and CE Mark approval in Europe, suggesting it may not yet have the same level of regulatory clearance or published clinical validation for its specific disease detection claims.
Pricing & Value
Tempus ECG-AFTempus ECG-AF has established CMS reimbursement (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025), providing clear financial value for healthcare facilities. Cardiomo's pricing details are not publicly available, though it previously offered a device at $200 with a $10 monthly subscription, making its current value proposition less transparent for enterprise adoption.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF is designed as a software solution integrated into healthcare facility systems and EHRs, with established FDA clearance and CMS reimbursement, indicating strong enterprise readiness. Cardiomo, while HIPAA compliant and cloud-based, relies on a wearable device and mobile app, which may present different integration challenges and scalability considerations within large healthcare enterprises compared to a purely software-based solution.
Innovation
TieBoth tools demonstrate significant innovation in their respective domains. Tempus ECG-AF leverages advanced AI for predictive risk assessment from standard ECGs, a novel approach to proactive AF identification. Cardiomo innovates with a medical-grade wearable for continuous, real-time, multi-parameter heart health monitoring and AI-powered alerts, pushing the boundaries of remote patient monitoring.
Support & Docs
TieBoth companies likely offer support and documentation, but specific details for enterprise-level support and comprehensive documentation are not extensively detailed in the provided information. Tempus mentions a cardiology support team, and Cardiomo provides a mobile application with real-time alerts and notifications, implying user support. Without more specific comparative information on SLAs, training, or extensive documentation portals, it's difficult to declare a definitive winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Cardiomo |
|---|---|---|
| Tool Name | Tempus ECG-AF | Cardiomo |
| Company | Tempus AI, Inc. | Cardiomo, Inc. |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | Medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, designed to detect cardiovascular diseases and provide timely alerts to users and caregivers. |
| Key Features | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients | Medical-grade wearable patch; Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature); AI-powered disease detection (arrhythmias, cardiovascular events); Real-time alerts and notifications; Mobile application (Android and iOS); HIPAA-compliant cloud analytics; Fall detection; Long battery life (up to 7-10 days) |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Cardiomo.
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or Cardiomo
Backers
Who funded each tool's parent company.